# Study to Evaluate the Safety, Tolerability and Efficacy of FOLFOX + CT-011 Versus FOLFOX Alone

> **NCT00890305** · PHASE2 · COMPLETED · sponsor: **Medivation, Inc.** · enrollment: 171 (actual)

## Conditions studied

- Metastatic Colorectal Cancer

## Interventions

- **DRUG:** CT-011
- **DRUG:** FOLFOX

## Key facts

- **NCT ID:** NCT00890305
- **Lead sponsor:** Medivation, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-05
- **Primary completion:** 2012-05
- **Final completion:** 2013-03
- **Target enrollment:** 171 (ACTUAL)
- **Last updated:** 2015-07-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00890305

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00890305, "Study to Evaluate the Safety, Tolerability and Efficacy of FOLFOX + CT-011 Versus FOLFOX Alone". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT00890305. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*